Status report on carbapenemases: challenges and prospects

References

• Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med.159(10), 1127–1132 (1999).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Weiner MG, Nachamkin I et al. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol.27(9), 893–900 (2006).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Synnestvedt M, Weiner MG et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol.31(1), 47–53 (2010).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Synnestvedt M, Weiner MG et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect. Control Hosp. Epidemiol.30(12), 1186–1192 (2009).
   PubMed Web of Science ®Google Scholar
• Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect. Control Hosp. Epidemiol.29(11), 996–1011 (2008).
   PubMed Web of Science ®Google Scholar
• Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant Gram-negative bacilli in North America. Pharmacotherapy28(2), 235–249 (2008).
   PubMed Web of Science ®Google Scholar
• Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control34(5 Suppl. 1), S20–S28; Discussion S64–S73 (2006).
   PubMed Web of Science ®Google Scholar
• Landman D, Bratu S, Kochar S et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J. Antimicrob. Chemother.60(1), 78–82 (2007).
   PubMedGoogle Scholar
• Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev.18(4), 657–686 (2005).
   PubMed Web of Science ®Google Scholar
• Young L, Sabel A, Price C. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect. Control Hosp. Epidemiol.28(11), 1247–1254 (2007).
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev.23(1), 160–201 (2010).
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci.289(1036), 321–331 (1980).
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother.54(3), 969–976 (2010).
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC β-lactamases. Clin. Microbiol. Rev.22(1), 161–182 (2009).
   PubMed Web of Science ®Google Scholar
• Pai H, Kang C-I, Byeon J-H et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-β lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother.48(10), 3720–3728 (2004).
   PubMed Web of Science ®Google Scholar
• Mammeri H, Guillon H, Eb F, Nordmann P. Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases. Antimicrob. Agents Chemother.54(11), 4556–4560 (2010).
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez L, Pascual A, Hernandez-Alles S et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother.43(7), 1669–1673 (1999).
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev.20(3), 440–458 (2007).
   PubMed Web of Science ®Google Scholar
• Bradford PA, Urban C, Mariano N et al. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the foss of an outer membrane protein. Antimicrob. Agents Chemother.41(3), 563–569 (1997).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Mariotte S, Naas T, Labia R, Nicolas MH. Biochemical properties of a carbapenem-hydrolyzing β-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrob. Agents Chemother.37(5), 939–946 (1993).
   PubMed Web of Science ®Google Scholar
• Pottumarthy S, Moland ES, Juretschko S et al. NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg. Infect. Dis.9(8), 999–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother.52(2), 570–573 (2008).
   PubMed Web of Science ®Google Scholar
• Rasmussen B, Bush K, Keeney D et al. Characterization of IMI-1 β-lactamase, a class A carbapenem- hydrolyzing enzyme from Enterobacter cloacae. Antimicrob. Agents Chemother.40(9), 2080–2086 (1996).
   PubMed Web of Science ®Google Scholar
• Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A β-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob. Agents Chemother.38(6), 1262–1270 (1994).
   PubMed Web of Science ®Google Scholar
• Queenan AM, Torres-Viera C, Gold HS et al. SME-type carbapenem-hydrolyzing class A β-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother.44(11), 3035–3039 (2000).
   PubMed Web of Science ®Google Scholar
• Queenan AM, Shang W, Schreckenberger P et al. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother.50(10), 3485–3487 (2006).
   PubMedGoogle Scholar
• Poirel L, Wenger A, Bille J et al. SME-2-producing Serratia marcescens isolate from Switzerland. Antimicrob. Agents Chemother.51(6), 2282–2283 (2007).
   PubMed Web of Science ®Google Scholar
• Carrer A, Poirel L, Pitout JD, Church D, Nordmann P. Occurrence of an SME-2-producing Serratia marcescens isolate in Canada. Int. J. Antimicrob. Agents.31(2), 181–182 (2008).
   PubMedGoogle Scholar
• Henriques I, Moura A, Alves A, Saavedra MJ, Correia A. Molecular characterization of a carbapenem-hydrolyzing class A β-lactamase, SFC-1, from Serratia fonticola UTAD54. Antimicrob. Agents Chemother.48(6), 2321–2324 (2004).
   PubMed Web of Science ®Google Scholar
• Girlich D, Poirel L, Nordmann P. Novel ambler class A carbapenem-hydrolyzing β-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. Antimicrob. Agents Chemother.54(1), 328–332 (2010).
   PubMedGoogle Scholar
• Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother.44(3), 622–632 (2000).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Mendes RE, Walsh TR, Gales AC, Jones RN. Emergence of the extended-spectrum β-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother.48(6), 2344–2345 (2004).
   PubMedGoogle Scholar
• Walther-Rasmussen J, Høiby N. Class A carbapenemases. J. Antimicrob. Chemother.60(3), 470–482 (2007).
   PubMed Web of Science ®Google Scholar
• Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J. Antimicrob. Chemother.49(3), 561–565 (2002).
   PubMed Web of Science ®Google Scholar
• Jeong SH, Bae IK, Kim D et al. First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum β-lactamases in Korea. Antimicrob. Agents Chemother.49(11), 4809–4810 (2005).
   PubMedGoogle Scholar
• da Fonseca ÉL, Vieira VV, Cipriano R, Vicente ACP. Emergence of blaGES-5 in clinical colistin-only-sensitive (COS) Pseudomonas aeruginosa strain in Brazil. J. Antimicrob. Chemother.59(3), 576–577 (2007).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis.9(4), 228–236 (2009).
   PubMed Web of Science ®Google Scholar
• Deshpande L, Rhomberg P, Sader H, Jones R. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999–2005). Diagn. Microbiol. Infect. Dis.56(4), 367–372 (2006).
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Patel J. Commentary: Klebsiella pneumoniae carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. Infect. Control Hosp. Epidemiol.29(12), 1107–1109 (2008).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer AM, Perez F et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J. Antimicrob. Chemother.63(3), 427–437 (2009).
   PubMed Web of Science ®Google Scholar
• Yigit H, Queenan AM, Rasheed JK et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother.47(12), 3881–3889 (2003).
   PubMed Web of Science ®Google Scholar
• Bratu S, Landman D, Alam M, Tolentino E, Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother.49(2), 776–778 (2005).
   PubMed Web of Science ®Google Scholar
• Villegas MV, Lolans K, Correa A et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob. Agents Chemother.51(4), 1553–1555 (2007).
   PubMed Web of Science ®Google Scholar
• Cai JC, Zhou HW, Zhang R, Chen G-X. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob. Agents Chemother.52(6), 2014–2018 (2008).
   PubMed Web of Science ®Google Scholar
• Rasheed JK, Biddle JW, Anderson KF et al. Detection of the Klebsiella pneumoniae carbapenemase type 2 carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid. J. Clin. Microbiol.46(6), 2066–2069 (2008).
   PubMedGoogle Scholar
• Miriagou V, Tzouvelekis LS, Rossiter S et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother.47(4), 1297–1300 (2003).
   PubMed Web of Science ®Google Scholar
• Tibbetts R, Frye JG, Marschall J, Warren D, Dunne W. Detection of KPC-2 in a clinical isolate of Proteus mirabilis and first reported description of carbapenemase resistance caused by a KPC β-lactamase in P. mirabilis. J. Clin. Microbiol.46(9), 3080–3083 (2008).
   PubMed Web of Science ®Google Scholar
• Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother.45(4), 1151–1161 (2001).
   PubMed Web of Science ®Google Scholar
• Wolter DJ, Kurpiel PM, Woodford N et al. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob. Agents Chemother.53(2), 557–562 (2009).
   PubMed Web of Science ®Google Scholar
• Robledo IE, Vasquez GJ, Aquino EE, Moland ES, Sante MI, Hanson ND. A novel KPC variant, KPC-6, in a Klebsiella pneumoniae (Kp) isolated in Puerto Rico (PR) C2–3738. Presented at: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting. Washington, DC, USA, 25–28 October 2008.
   Google Scholar
• Kitchel B, Rasheed JK, Patel JB et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob. Agents Chemother.53(8), 3365–3370 (2009).
   PubMed Web of Science ®Google Scholar
• Chen L, Mediavilla JR, Endimiani A et al. Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (blaKPC) variants. J. Clin. Microbiol.49(2), 579–585 (2010).
   PubMedGoogle Scholar
• Naas T, Cuzon G, Villegas M-V et al. Genetic structures at the origin of acquisition of the β-lactamase blaKPC gene. Antimicrob. Agents Chemother.52(4), 1257–1263 (2008).
   PubMed Web of Science ®Google Scholar
• Cuzon G, Naas T, Truong H et al. Worldwide diversity of Klebsiella pneumoniae that produce β-lactamase blaKPC-2 gene. Emerg. Infect. Dis.16(9), 1349–1356 (2010).
   PubMed Web of Science ®Google Scholar
• Kitchel B, Rasheed JK, Endimiani A et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother.54(10), 4201–4207 (2010).
   PubMed Web of Science ®Google Scholar
• Rice LB, Carias LL, Hutton RA et al. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob. Agents Chemother.52(9), 3427–3429 (2008).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Carias LL, Hujer AM et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob. Agents Chemother.52(7), 2680–2682 (2008).
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Schwaber MJ et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob. Agents Chemother.53(2), 818–820 (2009).
   PubMed Web of Science ®Google Scholar
• Pournaras S, Protonotariou E, Voulgari E et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J. Antimicrob. Chemother.64(2), 348–352 (2009).
   PubMed Web of Science ®Google Scholar
• Woodford N, Zhang J, Warner M et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J. Antimicrob. Chemother.62(6), 1261–1264 (2008).
   PubMed Web of Science ®Google Scholar
• Kitchel B, Sundin DR, Patel JB. Regional dissemination of KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother.53(10), 4511–4513 (2009).
   PubMedGoogle Scholar
• Qi Y, Wei Z, Ji S et al. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J. Antimicrob. Chemother. DOI: 10.1093/jac/dkq431 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.35(1), 147–151 (1991).
   PubMed Web of Science ®Google Scholar
• Lauretti L, Riccio ML, Mazzariol A et al. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother.43(7), 1584–1590 (1999).
   PubMed Web of Science ®Google Scholar
• Poirel L, Naas T, Nicolas D et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother.44(4), 891–897 (2000).
   PubMed Web of Science ®Google Scholar
• Giakkoupi P, Xanthaki A, Kanelopoulou M et al. VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J. Clin. Microbiol.41(8), 3893–3896 (2003).
   PubMed Web of Science ®Google Scholar
• Kassis-Chikhani N, Decre D, Gautier V et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J. Antimicrob. Chemother.57(1), 142–145 (2006).
   PubMedGoogle Scholar
• Giakkoupi P, Pappa O, Polemis M et al. Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. Antimicrob. Agents Chemother.53(9), 4048–4050 (2009).
   PubMed Web of Science ®Google Scholar
• Morfin-Otero R, Rodriguez-Noriega E, Deshpande LM, Sader HS, Castanheira M. Dissemination of a bla(VIM-2)-carrying integron among Enterobacteriaceae species in Mexico: report from the SENTRY Antimicrobial Surveillance Program. Microb. Drug Resist.15(1), 33–35 (2009).
   PubMed Web of Science ®Google Scholar
• Tato M, Morosini M, García L, Albertí S, Coque MT, Cantón R. Carbapenem heteroresistance in VIM-1 producing-Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J.Clin. Microbiol.48(11), 4089–4093 (2010).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a β-lactamase gene, blaGIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob. Agents Chemother.48(12), 4654–4661 (2004).
   PubMed Web of Science ®Google Scholar
• Toleman MA, Simm AM, Murphy TA et al. Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY Antimicrobial Surveillance Programme. J. Antimicrob. Chemother.50(5), 673–679 (2002).
   PubMed Web of Science ®Google Scholar
• Lee K, Yum JH, Yong D et al. Novel acquired metallo-β-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother.49(11), 4485–4491 (2005).
   PubMed Web of Science ®Google Scholar
• Yong D, Walsh TR, Bell J et al. A novel subgroup metallo β-lactamase, AIM-1, eerges in Pseudomonas aeruginosa from Australia. C2–3928. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA. 17–20 September 2007.
   Google Scholar
• Poirel L, Rodriguez-Martinez J-M, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P. Characterization of DIM-1, an integron-encoded metallo-β-lactamase from a Pseudomonas stutzeri clinical isolate in The Netherlands. Antimicrob. Agents Chemother.54(6), 2420–2424 (2010).
   PubMed Web of Science ®Google Scholar
• Sekiguchi J-I, Morita K, Kitao T et al. KHM-1, a novel plasmid-mediated metallo-β-lactamase from a Citrobacter freundii clinical isolate. Antimicrob. Agents Chemother.52(11), 4194–4197 (2008).
   PubMedGoogle Scholar
• Salabi AE, Toleman MA, Weeks J et al. First report of the metallo-β-lactamase SPM-1 in Europe. Antimicrob. Agents Chemother.54(1), 582 (2010).
   PubMed Web of Science ®Google Scholar
• Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother.53(12), 5046–5054 (2009).
   PubMed Web of Science ®Google Scholar
• Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob. Agents Chemother.54(11), 4914–4916 (2010).
   PubMed Web of Science ®Google Scholar
• Poirel L, Revathi G, Bernabeu S, Nordmann P. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob. Agents Chemother.55(2), 934–936 (2010).
   PubMedGoogle Scholar
• Poirel L, Al Maskari Z, Al Rashdi F, Bernabeu S, Nordmann P. NDM-1-producing Klebsiella pneumoniae isolated in the Sultanate of Oman. J. Antimicrob. Chemother.66(2), 304–306 (2010).
   PubMedGoogle Scholar
• Detection of Enterobacteriaceae isolates carrying metallo-β-lactamase – United States, 2010. MMWR Morb. Mortal. Wkly Rep.59(24), 750 (2010).
   PubMedGoogle Scholar
• Peirano G, Ahmed-Bentley J, Woodford N, Pitout J. The characteristics of a metallo-β-lactamase producing Escherichia coli isolated in Canada from a patient with recent travel to India, C1–675a. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Pfeifer Y, Witte W, Holfelder M et al. NDM-1-producing Escherichia coli in Germany. Antimicrob. Agents Chemother55(3), 1318–1319 (2010).
   PubMedGoogle Scholar
• Samuelsen O, Thilesen CM, Heggelund L et al. Identification of NDM-1-producing Enterobacteriaceae in Norway. J. Antimicrob. Chemother.66(3), 670–672 (2010).
   PubMedGoogle Scholar
• Struelens MJ, Monnet DL, Magiorakos AP, Santos O’Connor F, Giesecke J. New Delhi metallo-β-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill.15(46), 1–10 (2010).
   Google Scholar
• Poirel L, Ros A, Carricajo A et al. Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India. Antimicrob. Agents Chemother.55(1), 447–448 (2011).
   PubMed Web of Science ®Google Scholar
• Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. New Delhi metallo-B-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg. Infect. Dis. DOI: 10.3201/eid1701.101358 (2010) (Epub ahead of print).
   Google Scholar
• Zarfel G, Hoenigl M, Leitner E et al. Emergence of New Delhi metallo-B-lactamase, Austria. Emerg. Infect. Dis. DOI: 10.3201/eid1701.101331 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Poirel L, Hombrouck-Alet C, Freneaux C, Bernabeu S, Nordmann P. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis.10(12), 832 (2010).
   PubMedGoogle Scholar
• Bogaerts P, Verroken A, Jans B, Denis O, Glupczynski Y. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis.10(12), 831–832 (2010).
   PubMedGoogle Scholar
• Koh TH, Khoo CT, Wijaya L et al. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis.10(12), 828 (2010).
   PubMedGoogle Scholar
• Hammerum AM, Toleman MA, Hansen F et al. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis.10(12), 829–830 (2010).
   PubMedGoogle Scholar
• Leverstein-Van Hall MA, Stuart JC, Voets GM et al. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis.10(12), 830–831 (2010).
   PubMed Web of Science ®Google Scholar
• Gottig S, Pfeifer Y, Wichelhaus TA et al. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect. Dis.10(12), 828–829 (2010).
   PubMedGoogle Scholar
• Chihara S, Okuzumi K, Yamamoto Y, Oikawa S, Hishinuma A. First case of New Delhi metallo-β-lactamase 1-producing Escherichia coli infection in Japan. Clin. Infect. Dis.52(1), 153–154 (2011).
   PubMed Web of Science ®Google Scholar
• Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis.11(5), 355–362 (2011).
   PubMed Web of Science ®Google Scholar
• Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis.10(9), 597–602 (2010).
   PubMed Web of Science ®Google Scholar
• Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J. Antimicrob. Chemother.65(10), 2253–2254 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1 producing A. baumannii in China. J. Antimicrob. Chemother. DOI: 10.1093/jac/dkr082 (2011) (Epub ahead of print).
   Google Scholar
• Zhang H, Hao Q. Crystal Structure of NDM-1 reveals a common β-lactam hydrolysis mechanism. FASEB J. DOI: fj.11-184036 (2011) (Epub ahead of print).
   Google Scholar
• Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob. Agents Chemother.54(1), 24–38 (2010).
   PubMed Web of Science ®Google Scholar
• Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect.12(9), 826–836 (2006).
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hujer KM et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.51(10), 3471–3484 (2007).
   PubMed Web of Science ®Google Scholar
• Bertini A, Poirel L, Bernabeu S et al. Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii. Antimicrob. Agents Chemother.51(7), 2324–2328 (2007).
   PubMed Web of Science ®Google Scholar
• Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob. Agents Chemother.51(4), 1530–1533 (2007).
   PubMed Web of Science ®Google Scholar
• Brown S, Young HK, Amyes SGB. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin. Microbiol. Infect.11(1), 15–23 (2005).
   PubMed Web of Science ®Google Scholar
• Brown S, Amyes SGB. The sequences of seven class D β-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents. Clin. Microbiol. Infect.11(4), 326–329 (2005).
   PubMedGoogle Scholar
• Heritier C, Poirel L, Fournier P-E et al. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob. Agents Chemother.49(10), 4174–4179 (2005).
   PubMed Web of Science ®Google Scholar
• Culebras E, Gonzalez-Romo F, Head J et al. Outbreak of Acinetobacter baumannii producing OXA-66 in a Spanish hospital: epidemiology and study of patient movements. Microb. Drug Resist.16(4), 309–315 (2010).
   PubMedGoogle Scholar
• Figueiredo S, Poirel L, Croize J, Recule C, Nordmann P. In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural blaOXA-66 oxacillinase gene. Antimicrob. Agents Chemother.53(6), 2657–2659 (2009).
   PubMedGoogle Scholar
• Paton R, Miles RS, Hood J, Amyes SG. ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int. J. Antimicrob. Agents.2(2), 81–87 (1993).
   PubMedGoogle Scholar
• Dalla-Costa LM, Coelho JM, Souza HA et al. Outbreak of carbapenem-resistant Acinetobacter baumannii Producing the OXA-23 enzyme in Curitiba, Brazil. J. Clin. Microbiol.41(7), 3403–3406 (2003).
   PubMed Web of Science ®Google Scholar
• Jeon B-C, Jeong SH, Bae IK et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 β-lactamase in Korea. J. Clin. Microbiol.43(5), 2241–2245 (2005).
   PubMed Web of Science ®Google Scholar
• Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg. Infect. Dis.16(1), 35–40 (2010).
   PubMed Web of Science ®Google Scholar
• Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother.45(2), 583–588 (2001).
   PubMed Web of Science ®Google Scholar
• Bonnet R, Marchandin H, Chanal C et al. Chromosome-encoded class D β-lactamase OXA-23 in Proteus mirabilis. Antimicrob. Agents Chemother.46(6), 2004–2006 (2002).
   PubMed Web of Science ®Google Scholar
• Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Chemother.44(6), 1556–1561 (2000).
   PubMed Web of Science ®Google Scholar
• Sevillano E, Gallego L, García-Lobo JM. First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii. Pathologie Biologie57(6), 493–495 (2009).
   PubMedGoogle Scholar
• Da Silva GJ, Quinteira S, Bértolo E et al. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian peninsula. J. Antimicrob. Chemother.54(1), 255–258 (2004).
   PubMed Web of Science ®Google Scholar
• Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob. Agents Chemother.50(9), 2941–2945 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez-Otsoa F, Gallego L, Towner KJ et al. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in Northern Spain. J. Clin. Microbiol.40(12), 4741–4743 (2002).
   PubMed Web of Science ®Google Scholar
• Poirel L, Marque S, Heritier C et al. OXA-58, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob. Agents Chemother.49(1), 202–208 (2005).
   PubMed Web of Science ®Google Scholar
• Pournaras S, Markogiannakis A, Ikonomidis A et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J. Antimicrob. Chemother.57(3), 557–561 (2006).
   PubMed Web of Science ®Google Scholar
• Hujer KM, Hujer AM, Hulten EA et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother.50(12), 4114–4123 (2006).
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hulten EA et al. Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility. Am. J. Infect. Control38(1), 63–65 (2010).
   PubMedGoogle Scholar
• Scott P, Deye G, Srinivasan A et al. An outbreak of multidrug-resistant Acinetobacter baumannii–calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin. Infect. Dis.44(12), 1577–1584 (2007).
   PubMed Web of Science ®Google Scholar
• Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother.48(1), 15–22 (2004).
   PubMed Web of Science ®Google Scholar
• Carrer A, Poirel L, Yilmaz M et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob. Agents Chemother.54(3), 1369–1373 (2010).
   PubMed Web of Science ®Google Scholar
• Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydrolyzing class D β-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother.53(12), 5035–5038 (2009).
   PubMed Web of Science ®Google Scholar
• Antonio CS, Neves PR, Medeiros M et al. High prevalence of carbapenem-resistant Acinetobacter baumannii carrying the blaOXA-143 gene in Brazilian hospitals. Antimicrob. Agents Chemother.55, 1322–1323 (2010).
   PubMedGoogle Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis.40, 1333–1341 (2005).
   PubMed Web of Science ®Google Scholar
• Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin. Microbiol. Rev.21(3), 449–465 (2008).
   PubMed Web of Science ®Google Scholar
• Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother.54(6), 2732–2734 (2010).
   PubMed Web of Science ®Google Scholar
• Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother.56(1), 128–132 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother.65(6), 1119–1125 (2010).
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.50(9), 2946–2950 (2006).
   PubMed Web of Science ®Google Scholar
• Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother.52(1), 351–352 (2008).
   PubMed Web of Science ®Google Scholar
• Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother.59(3), 473–477 (2007).
   PubMed Web of Science ®Google Scholar
• Poudyal A, Howden BP, Bell JM et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother.62(6), 1311–1318 (2008).
   PubMed Web of Science ®Google Scholar
• Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol.47(5), 1611–1612 (2009).
   PubMed Web of Science ®Google Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis.41(Suppl. 5), S303–S314 (2005).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn. Microbiol. Infect. Dis.52(3), 209–213 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother.63(4), 775–780 (2009).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Patel G, Hujer KM et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother.54(1), 526–529 (2010).
   PubMed Web of Science ®Google Scholar
• Wang YF, Dowzicky MJ. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn. Microbiol. Infect. Dis.68(1), 73–79 (2010).
   PubMedGoogle Scholar
• Hussein K, Sprecher H, Mashiach T et al. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol.30(7), 666–671 (2009).
   PubMed Web of Science ®Google Scholar
• Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis.46(4), 567–570 (2008).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother.59(1), 128–131 (2007).
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother.59(4), 772–774 (2007).
   PubMed Web of Science ®Google Scholar
• DiPersio JR, Dowzicky MJ. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial. Int. J. Antimicrob. Agents.29(5), 518–527 (2007).
   PubMed Web of Science ®Google Scholar
• Nguyen M, Eschenauer GA, Bryan M et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn. Microbiol. Infect. Dis.67(2), 180–184 (2010).
   PubMed Web of Science ®Google Scholar
• Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J. Chemother.19(6), 753–754 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. Infect. Dis.27(6), 439–443 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents.34(2), 111–120 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rojas A, Couce A, Blazquez J. Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.54(11), 4948–4949 (2010).
   PubMed Web of Science ®Google Scholar
• Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit. Care Med.37(6), 2071–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Perrott J, Mabasa VH, Ensom MH. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann. Pharmacother.44(3), 557–564 (2010).
   PubMed Web of Science ®Google Scholar
• Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother.54(10), 4112–4115 (2010).
   PubMed Web of Science ®Google Scholar
• Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002–2006 OPTAMA programs for US hospitals: focus on Gram-negative resistance. Ann. Pharmacother.43(2), 220–227 (2009).
   PubMedGoogle Scholar
• Bulik CC, Christensen H, Li P et al. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother.54(2), 804–810 (2010).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J. Antimicrob. Chemother.62(5), 1053–1056 (2008).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Choudhary Y, Bonomo RA. In vitro Activity of NXL104 in combination with β -lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother.53(8), 3599–3601 (2009).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother.65(7), 1428–1432 (2010).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother.55(1), 390–394 (2011).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J. Antimicrob. Chemother.65(11), 2376–2381 (2010).
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Bethel CR, Distler AM et al. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob. Agents Chemother.54(2), 890–897 (2010).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Bethel C, Choudhary Y, Bonomo RA. In vitro activity of penem-1 in combination with β-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother.54(4), 1650–1651 (2010).
   PubMedGoogle Scholar
• Endimiani A, Hujer KM, Hujer AM et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother.53(10), 4504–4507 (2009).
   PubMed Web of Science ®Google Scholar
• Landman D, Babu E, Shah N et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J. Antimicrob. Chemother.65(10), 2123–2127 (2010).
   PubMed Web of Science ®Google Scholar
• Aggen JB, Armstrong ES, Goldblum AA et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother.54(11), 4636–4642 (2010).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother.66(1), 48–53 (2011).
   PubMed Web of Science ®Google Scholar
• Vaara M, Siikanen O, Apajalahti J, Frimodt-Moller N, Vaara T. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J. Antimicrob. Chemother.65(5), 942–945 (2010).
   PubMedGoogle Scholar
• Mushtaq S, Warner M, Livermore D. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J. Antimicrob. Chemother.65(2), 266–270 (2010).
   PubMed Web of Science ®Google Scholar
• Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin. Infect. Dis.49(2), 271–274 (2009).
   PubMed Web of Science ®Google Scholar
• Perez F, Endimiani A, Ray AJ et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J. Antimicrob. Chemother.65(8), 1807–1818 (2010).
   PubMed Web of Science ®Google Scholar
• Aschbacher R, Pagani L, Doumith M et al. Metallo-β-lactamases among Enterobacteriaceae from routine samples in an Italian tertiary care hospital and long-term care facilities during 2008. Clin. Microbiol. Infect.17(2), 181–189 (2010).
   Google Scholar
• Boucher H, Talbot G, Bradley J et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin. Infect. Dis.48(1), 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Tillotson G. Stimulating antibiotic development. Lancet Infect. Dis.10(1), 2–3 (2010).
   PubMedGoogle Scholar
• Calfee D, Jenkins SG. Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect. Control Hosp. Epidemiol.29(10), 966–968 (2008).
   PubMed Web of Science ®Google Scholar
• Ben David D, Maor Y, Keller N et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect. Control Hosp. Epidemiol.31(6), 620–626 (2010).
   PubMedGoogle Scholar
• Kochar S, Sheard T, Sharma R et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol.30(5), 447–452 (2009).
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Hayden MK, Lolans K et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase–producing K. pneumoniae at a long-term acute care hospital. Infect. Control Hosp. Epidemiol.31(4), 341–347 (2010).
   PubMedGoogle Scholar
• Bilavsky E, Schwaber MJ, Carmeli Y. How to stem the tide of carbapenemase-producing Enterobacteriaceae?: proactive versus reactive strategies. Curr. Opin. Infect. Dis.23(4), 327–331 (2010).
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Akova M, Cornaglia G et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin. Microbiol. Infect.16(2), 102–111 (2010).
   PubMed Web of Science ®Google Scholar
• Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb. Mortal. Wkly Rep.58(10), 256–260 (2009).
   PubMedGoogle Scholar
• Yu Y-S, Du X-X, Zhou Z-H, Chen Y-G, Li L-J. First Isolation of blaIMI-2 in an Enterobacter cloacae clinical isolate from China. Antimicrob. Agents Chemother.50(4), 1610–1611 (2006).
   PubMedGoogle Scholar
• Aubron C, Poirel L, Ash RJ, Nordmann P. Carbapenemase-producing Enterobacteriaceae, U.S. rivers. Emerg. Infect. Dis.11(2), 260–264 (2005).
   PubMed Web of Science ®Google Scholar
• Wachino JC, Doi Y, Yamane K et al. Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A β-lactamase, GES-4, possessing a single G170S substitution in the Ω-Loop. Antimicrob. Agents Chemother.48(8), 2905–2910 (2004).
   PubMed Web of Science ®Google Scholar
• Ambretti S, Gaibani P, Caroli F, Miragliotta L, Sambri V. A carbapenem-resistant Klebsiella pneumoniae isolate harboring KPC-1 from Italy. New Mirobiol.33(3), 281–282 (2010).
   PubMedGoogle Scholar
• Robledo IE, Aquino EE, Sante MI et al. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob. Agents Chemother.54(3), 1354–1357 (2010).
   PubMed Web of Science ®Google Scholar
• Woodford N, Tierno PM Jr, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother.48(12), 4793–4799 (2004).
   PubMed Web of Science ®Google Scholar
• Robledo IE, Moland ES, Aquino EA et al. First report of a KPC-4 and CTX-M producing K. pneumoniae (KP) isolated from Puerto Rico. Presented at: 47th InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
   Google Scholar
• Palepou MF, Woodford N, Hope R et al. Novel class A carbapenemase, KPC-4, in an Enterobacter isolate from Scotland. 1134_01_20. Presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, 2–5 April 2005.
   Google Scholar
• Gregory CJ, Llata E, Stine N et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect. Control Hosp. Epidemiol.31(5), 476–484 (2010).
   PubMed Web of Science ®Google Scholar
• Kaase M, Normann P, Wichelhaus TA, Gatermann SG, Bonnin RA, Poirel L. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J. Antimicrob. Chemother. DOI: 10.1093/jac/dkr135 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Evans BA, Brown S, Hamouda A, Findlay J, Amyes SGB. Eleven novel OXA-51-like enzymes from clinical isolates of Acinetobacter baumannii. Clin. Microbiol. Infect.13(11), 1137–1138 (2007).
   PubMedGoogle Scholar